# Genesis Molecular AI

> AI-first drug discovery company using generative models for small-molecule design.

## Why it is interesting

Genesis Molecular AI raised $200M to scale its GEMS platform; a16z led the seed and co-led Series B with Menlo Ventures. Rebranded from Genesis Therapeutics.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** ai-ml, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series B (2023): $200M co-led by a16z Bio + Health (/fund/andreessen-horowitz) with Menlo Ventures (/fund/menlo-ventures) (BusinessWire)
- Rebranded from Genesis Therapeutics to Genesis Molecular AI; GEMS platform for small-molecule drug discovery
- Pharma partnerships include Genentech (2020) and Eli Lilly (2022)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/menlo-ventures

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/genesis-molecular-ai